Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Recommendation of “Hold” by Brokerages

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has been assigned a consensus rating of “Hold” from the five analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $38.6667.

A number of equities research analysts recently issued reports on the company. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Wall Street Zen downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Canaccord Genuity Group raised their price target on shares of Pharming Group from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Zacks Research downgraded shares of Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th.

Institutional Trading of Pharming Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC acquired a new position in Pharming Group during the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC bought a new stake in shares of Pharming Group during the 4th quarter worth approximately $224,000. Millennium Management LLC bought a new stake in shares of Pharming Group during the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC boosted its holdings in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after buying an additional 28,615 shares during the last quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Price Performance

PHAR stock opened at $11.83 on Thursday. The stock has a 50-day moving average price of $12.70 and a two-hundred day moving average price of $14.75. The stock has a market cap of $837.33 million, a PE ratio of 98.58 and a beta of -0.01. The company has a current ratio of 3.01, a quick ratio of 2.31 and a debt-to-equity ratio of 0.34. Pharming Group has a 1 year low of $9.62 and a 1 year high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). The firm had revenue of $90.20 million during the quarter, compared to analyst estimates of $99.52 million. Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Equities analysts forecast that Pharming Group will post 0.25 EPS for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.